Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The percentage of women undergoing an induction of labor (IOL) is estimated to be 20% and continues to rise. Simultaneously, the cesarean delivery (CD) rate has continued to increase (2). Induction is a known risk factor for CD. Despite numerous studies evaluating time periods to define a failed IOL, there are no guidelines or accepted definitions of when to call an IOL failed given the incremental gain in vaginal delivery when IOL is prolonged. While decreasing the CD rate is an important primary focus in obstetrics, attention must also be paid to the overall length of labor given that prolonged labor is associated with adverse maternal and neonatal outcomes. Furthermore, a prolonged labor is associated with an increase in direct hospital costs and healthcare utilization. The use of cervical ripening agents, such as vaginal prostaglandin and mechanical dilators, has been demonstrated to reduce labor time and CD rate. In addition to specific individual agents, certain dosing and regimens for IOL and active labor have been compared to evaluate whether a particular dose or regimen can decrease the length of labor and decrease the CD rate. Most of these regimens; however, focus on individual induction agents and few have compared the efficacy of using more than one agent simultaneously. Given the associated risks of prolonged labor and limited data evaluating the use of combined cervical ripening agents, our objective is to evaluate the difference in time to delivery among women who undergo an IOL with four different methods.
Prolonged labor increases the risk of maternal and neonatal morbidity as well as increases healthcare costs. There is limited data evaluating the use of two simultaneous induction agents to decrease the time to delivery.
Maternal and neonatal morbidity with prolonged labor The adverse maternal and neonatal morbidity association with prolonged labor has been demonstrated in numerous studies. An increase in maternal risk of post partum hemorrhage and endometritis has been associated with prolonged labor. Cheng et al demonstrated that the risk of post partum hemorrhage and endometritis significantly increased with increasing length of labor. Maghoma et al evaluated the latent phase of labor and found a similar increased risk in endometritis but also noted a significant risk in maternal sepsis with a prolonged latent phase of labor.
Neonatal outcomes are similarly improved with a shorter duration of labor. In addition to the risk of chorioamnionitis and decreased 5 minute Apgar score, there is also a significantly increased risk of neonatal intensive care unit admission as well as neonatal sepsis with prolonged labor.
Increased healthcare utilization with prolonged labor Both direct and indirect medical costs have been evaluated in the obstetrics literature. A prolonged labor has been associated with an increase in direct and indirect medical costs as well as an increase in healthcare utilization. Mackenzie et al evaluated the cost of different induction regimens and found a decreased cost for women that remained on the antenatal unit for a shorter period of time.
Use of simultaneous induction agents Pettker et al evaluated the use of a transcervical foley with and without oxytocin and found no difference in mode of delivery or delivery within 24 hours. They found that labor was 2.5 hours shorter with the addition of oxytocin although the study was not powered to see a statistical difference. Other studies have looked at the concurrent use of prostaglandin with cervical foley. Barrilleaux et al evaluated the use of oral misoprostol with cervical foley compared to cervical foley alone and found no difference in time to delivery; however, the use of oral misprostol has well known side effects, including a high rate of tachysystole which was found in this study. Hill et al reported a decreased time to second stage and time to delivery with the use of cervical foley and oral misoprostol compared to vaginal misoprostol alone; however this was a small study that used with a higher, more favorable starting Bishop score in the combined foley+misoprostol group, biasing them away from the null. Standardized time cut offs during IOL were not used in this study. Recently, Carbone et al performed a randomized trial comparing foley bulb and misprostol to misoprostol alone and found a decreased time to delivery among those in the combined group. This study was a small trial with 60 patients in each arm and did not compare the combined agents to cervical foley alone.
Standardization of IOL The optimal length for an IOL is not well established and data on definitions of a failed IOL and prolonged latent phase are lacking. Multiple studies have shown that within 6 hours of oxytocin administration, 60-70% of patients are in active labor. Although data suggest that the longer latent labor is allowed to proceed, the more women that will deliver vaginally, there is also evidence of an increased risk of morbidity, without a large incremental gain. Certain dosing and regimens of individual agents have been evaluated to try and decrease labor; however, studies have not evaluated the use of time cut offs during an IOL to help reduce variation in practice and standardize the IOL process.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cervical foley & Misoprostol | Experimental | Patients randomized to this arm will receive a cervical foley and misoprostol to induce their labor. |
|
| Misoprostol only | Experimental | Patients randomized to this arm will receive misoprostol only to induce their labor. |
|
| Cervical foley alone | Experimental | Patients randomized to this arm will receive a cervical foley to induce their labor. |
|
| Cervical foley & Pitocin | Experimental | Patients randomized to this arm will receive a cervical foley and pitocin to induce their labor. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cervical Foley & Misoprostol | Device | A cervical foley combined with misoprostol will be used to induce the patient. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Time to Delivery | Amount of hours that pass between the start of the induction to delivery. | Hours between start of induction to delivery |
| Length of Stay | Total maternal length of stay as defined as days from the day the induction began to the day of discharge | Days between admit to hospital and discharge |
| Severe RDS | enrollment through neonatal discharge |
| Measure | Description | Time Frame |
|---|---|---|
| Mode of Delivery | Cesarean Delivery | Start of induction to delivery |
| Time to Active Labor | Start of induction to active labor | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lisa D Levine, MD | University of Pennsylvania | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36996264 | Derived | de Vaan MD, Ten Eikelder ML, Jozwiak M, Palmer KR, Davies-Tuck M, Bloemenkamp KW, Mol BWJ, Boulvain M. Mechanical methods for induction of labour. Cochrane Database Syst Rev. 2023 Mar 30;3(3):CD001233. doi: 10.1002/14651858.CD001233.pub4. | |
| 27824758 | Derived | Levine LD, Downes KL, Elovitz MA, Parry S, Sammel MD, Srinivas SK. Mechanical and Pharmacologic Methods of Labor Induction: A Randomized Controlled Trial. Obstet Gynecol. 2016 Dec;128(6):1357-1364. doi: 10.1097/AOG.0000000000001778. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Cervical Foley & Misoprostol | Patients randomized to this arm will receive a cervical foley and misoprostol to induce their labor. Cervical Foley & Misoprostol: A cervical foley combined with misoprostol will be used to induce the patient. |
| FG001 | Misoprostol Only | Patients randomized to this arm will receive misoprostol to induce their labor. Misoprostol Alone: Misoprostol will be used alone to induce the patient |
| FG002 | Cervical Foley Alone | Patients randomized to this arm will receive a cervical foley to induce their labor. Cervical Foley Alone: A cervical foley alone will be used to induce the patient |
| FG003 | Cervical Foley & Pitocin | Patients randomized to this arm will receive a cervical foley and pitocin to induce their labor. Cervical Foley & Oxytocin: A cervical foley combined with oxytocin will be used to induce the patient |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Cervical Foley & Misoprostol | Patients randomized to this arm will receive a cervical foley and misoprostol to induce their labor. Cervical Foley & Misoprostol: A cervical foley combined with misoprostol will be used to induce the patient. |
| BG001 | Misoprostol Only |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Time to Delivery | Amount of hours that pass between the start of the induction to delivery. | Posted | Median | Inter-Quartile Range | Hours | Hours between start of induction to delivery |
|
Up to 6 weeks postpartum.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Cervical Foley & Misoprostol | Patients randomized to this arm will receive a cervical foley and misoprostol to induce their labor. Cervical Foley & Misoprostol: A cervical foley combined with misoprostol will be used to induce the patient. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Chorioamnionitis | Pregnancy, puerperium and perinatal conditions | Chorioamnionitis | Non-systematic Assessment | Defined by use of antibiotics during labor not for GBS+ or other known infection. |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Lisa Levine | University of Pennsylvania | 2156626913 | lisa.levine@uphs.upenn.edu |
Not provided
| ID | Term |
|---|---|
| D016595 | Misoprostol |
| ID | Term |
|---|---|
| D011459 | Prostaglandins E, Synthetic |
| D011465 | Prostaglandins, Synthetic |
| D011453 | Prostaglandins |
| D015777 | Eicosanoids |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Misoprostol Alone | Drug | Misoprostol will be used alone to induce the patient |
|
|
| Cervical Foley Alone | Device | A cervical foley alone will be used to induce the patient |
|
| Cervical Foley & Pitocin | Device | A cervical foley combined with pitocin will be used to induce the patient |
|
|
| Regional Anesthesia |
| During delivery |
| Chorioamnionitis | Enrollment through deischarge |
| Maternal Morbidity | Enrollment through discharge |
Patients randomized to this arm will receive misoprostol to induce their labor. Misoprostol Alone: Misoprostol will be used alone to induce the patient |
| BG002 | Cervical Foley Alone | Patients randomized to this arm will receive a cervical foley to induce their labor. Cervical Foley Alone: A cervical foley alone will be used to induce the patient |
| BG003 | Cervical Foley & Pitocin | Patients randomized to this arm will receive a cervical foley and pitocin to induce their labor. Cervical Foley & Pitocin: A cervical foley combined with pitocin will be used to induce the patient |
| BG004 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Median | Inter-Quartile Range | Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| OG002 |
| Cervical Foley Alone |
Patients randomized to this arm will receive a cervical foley to induce their labor. Cervical Foley Alone: A cervical foley alone will be used to induce the patient |
| OG003 | Cervical Foley & Pitocin | Patients randomized to this arm will receive a cervical foley and pitocin to induce their labor. Cervical Foley & Pitocin: A cervical foley combined with pitocin will be used to induce the patient |
|
|
| Primary | Length of Stay | Total maternal length of stay as defined as days from the day the induction began to the day of discharge | Posted | Median | Inter-Quartile Range | Days | Days between admit to hospital and discharge |
|
|
|
| Primary | Severe RDS | Posted | Number | participants | enrollment through neonatal discharge |
|
|
|
| Secondary | Mode of Delivery | Cesarean Delivery | Posted | Number | participants | Start of induction to delivery |
|
|
|
| Secondary | Time to Active Labor | Posted | Median | Inter-Quartile Range | Hours | Start of induction to active labor |
|
|
|
| Secondary | Regional Anesthesia | Posted | Number | participants | During delivery |
|
|
|
| Secondary | Chorioamnionitis | Posted | Number | participants | Enrollment through deischarge |
|
|
|
| Secondary | Maternal Morbidity | Posted | Number | participants | Enrollment through discharge |
|
|
|
| 0 |
| 123 |
| 30 |
| 123 |
| EG001 | Misoprostol Only | Patients randomized to this arm will receive misoprostol to induce their labor. Misoprostol Alone: Misoprostol will be used alone to induce the patient | 0 | 120 | 33 | 120 |
| EG002 | Cervical Foley Alone | Patients randomized to this arm will receive a cervical foley to induce their labor. Cervical Foley Alone: A cervical foley alone will be used to induce the patient | 0 | 123 | 46 | 123 |
| EG003 | Cervical Foley & Pitocin | Patients randomized to this arm will receive a cervical foley and pitocin to induce their labor. Cervical Foley & Oxytocin: A cervical foley combined with oxytocin will be used to induce the patient | 0 | 125 | 46 | 125 |
|
| Endometritis | Pregnancy, puerperium and perinatal conditions | Endometritis | Non-systematic Assessment | Diagnosed and treated based on maternal fever (>100.4) in the setting of either (1) fundal tenderness or (2) maternal tachycardia |
|
| Wound Infection | Pregnancy, puerperium and perinatal conditions | Wound Infection | Non-systematic Assessment | Diagnosed on chart review by provider documenting a diagnosis of cellulitis, need for antibiotics to treat wound, wound separation, purulent discharge from wound, abscess, or need for debridement. |
|
| Venous Thromboembolism | Pregnancy, puerperium and perinatal conditions | Venous Thromboemboli | Non-systematic Assessment |
|
| Maternal blood transfusion | Pregnancy, puerperium and perinatal conditions | Non-systematic Assessment |
|
| Postpartum readmission | Pregnancy, puerperium and perinatal conditions | Non-systematic Assessment |
|
| NICU admission | Pregnancy, puerperium and perinatal conditions | Non-systematic Assessment |
|
| Neonatal blood transfusion | Pregnancy, puerperium and perinatal conditions | Non-systematic Assessment |
|
| Hypoxic-ischemic encephalopathy | Pregnancy, puerperium and perinatal conditions | Non-systematic Assessment |
|
| Intraventricular hemorrhage Grade 3 or 4 | Pregnancy, puerperium and perinatal conditions | Non-systematic Assessment |
|
| Severe respiratory distress | Pregnancy, puerperium and perinatal conditions | Non-systematic Assessment | Intubation and mechanical ventilation for a minimum of 12 hours. |
|
| Necrotizing enterocolitis or rule out NEC | Pregnancy, puerperium and perinatal conditions | Non-systematic Assessment |
|
| Culture proven neonatal sepsis | Pregnancy, puerperium and perinatal conditions | Non-systematic Assessment |
|
| Presumed Sepsis | Pregnancy, puerperium and perinatal conditions | Non-systematic Assessment |
|
Not provided
Not provided
| D005231 |
| Fatty Acids, Unsaturated |
| D005227 | Fatty Acids |
| D008055 | Lipids |
| D012898 | Autacoids |
| D018836 | Inflammation Mediators |
| D001685 | Biological Factors |